Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration

Acta Ophthalmologica

Volumn 93, Issue 6, 2015, Pages 524-532

  Shin, Joo Youn ^a   Kwon, Kye Yoon ^a   Byeon, Suk Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

age related macular degeneration; antivascular endothelial growth factor; choroidal thickness; optical coherence tomography; polypoidal choroidal vasculopathy

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CHOROIDAL THICKNESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; PRIORITY JOURNAL; REFRACTION ERROR; SUBRETINAL FLUID; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CHOROID; CHOROIDAL NEOVASCULARIZATION; COMPARATIVE STUDY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYPS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROID; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; ORGAN SIZE; POLYPS; RANIBIZUMAB; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84947031784     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12653     Document Type: Article

References (41)

1. Akaza E, Mori R, &, Yuzawa M, (2008): Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 28: 717-722.
2. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, &, Mahajan VB, (2013): Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156: 15-22.
3. Branchini LA, Adhi M, Regatieri CV, Nandakumar N, Liu JJ, Laver N, Fujimoto JG, &, Duker JS, (2013): Analysis of choroidal morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. Ophthalmology 120: 1901-1908.
4. Brown DM, Chen E, Mariani A, Major JC Jr, & SAVE StudyGroup (2013): Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 120: 349-354.
5. Cao J, McLeod S, Merges CA, &, Lutty GA, (1998): Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol 116: 589-597.
6. Chung SE, Kang SW, Lee JH, &, Kim YT, (2011): Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118: 840-845.
7. Congdon N, O'Colmain B, Klaver CCW, et al., (2004): Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122: 477-485.
8. Ding X, Li J, Zeng J, Ma W, Liu R, Li T, Yu S, &, Tang S, (2011): Choroidal thickness in healthy Chinese subjects. Invest Ophthalmol Vis Sci 52: 9555-9560.
9. Ferris FL, Davis MD, Clemons TE, et al., (2005): A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 123: 1570-1574.
10. Finger RP, Wiedemann P, Blumhagen F, Pohl K, &, Holz FG, (2013): Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91: 540-546.
11. Friedman E, Smith TR, Kuwabara T, &, Beyer CK, (1964): Choroidal vascular patterns in hypertension. Arch Ophthalmol 71: 842-850.
12. Grossniklaus HE, &, Green WR, (2004): Choroidal neovascularization. Am J Ophthalmol 137: 496-503.
13. Hayashi H, Yamashiro K, Tsujikawa A, Ota M, Otani A, &, Yoshimura N, (2009): Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. Am J Ophthalmol 148: 83-89.
14. Jirarattanasopa P, Ooto S, Nakata I, Tsujikawa A, Yamashiro K, Oishi A, &, Yoshimura N, (2012): Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 53: 3663-3672.
15. Kang HM, Kwon HJ, Yi JH, Lee CS, &, Lee SC, (2014): Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 157: 1013-1021.
16. Kim S-W, Oh J, Kwon S-S, Yoo J, &, Huh K, (2011): Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 31: 1904-1911.
17. Koh A, Lee WK, Chen L-J, et al., (2012): EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32: 1453-1464.
18. Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, &, Kinoshita S, (2011): Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249: 1123-1128.
19. Koizumi H, Yamagishi T, Yamazaki T, &, Kinoshita S, (2013): Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol 155: 305-313.
20. Kokame GT, Yeung L, &, Lai JC, (2010): Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94: 297-301.
21. Lala C, Framme C, Wolf-Schnurrbusch UEK, &, Wolf S, (2013): Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol 91: 526-530.
22. Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, &, Aung T, (2010): Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29: 19-29.
23. Manjunath V, Taha M, Fujimoto JG, &, Duker JS, (2010): Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol 150: 325-329.
24. Manjunath V, Goren J, Fujimoto JG, &, Duker JS, (2011): Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol 152: 663-668.
25. Margolis R, &, Spaide RF, (2009): A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 147: 811-815.
26. Maruko I, Iida T, Sugano Y, Saito M, &, Sekiryu T, (2011): Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151: 594-603.
27. Maruko I, Iida T, Oyamada H, Sugano Y, Ojima A, &, Sekiryu T, (2013): Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol 156: 548-556.
28. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, &, Lutty GA, (2009): Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci 50: 4982-4991.
29. Mendrinos E, Mangioris G, Papadopoulou DN, Donati G, &, Pournaras CJ, (2013): Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Acta Ophthalmol 91: e184-e190.
30. Metelitsina TI, Grunwald JE, DuPont JC, Ying G-S, Brucker AJ, &, Dunaief JL, (2008): Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 358-363.
31. Mori K, Gehlbach PL, Ito YN, &, Yoneya S, (2005): Decreased arterial dye-filling and venous dilation in the macular choroid associated with age-related macular degeneration. Retina 25: 430-437.
32. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, &, de Jong PT, (1994): Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 35: 2857-2864.
33. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, & MARINA StudyGroup (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
34. Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, &, Yoshimura N, (2006): Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 142: 601-607.
35. Spaide RF, Hall L, Haas A, et al., (1996): Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16: 203-213.
36. Spaide RF, Koizumi H, Pozzoni MC, &, Pozonni MC, (2008): Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146: 496-500.
37. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, &, Lopez PF, (2012): Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32: 434-457.
38. Tozer K, Roller AB, Chong LP, et al., (2013): Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 120: 2029-2034.
39. Verteporfin Roundtable Participants (2005): Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25: 119-134.
40. Wei WB, Xu L, Jonas JB, et al., (2013): Subfoveal choroidal thickness: the Beijing Eye Study. Ophthalmology 120: 175-180.
41. Yamashiro K, Tomita K, Tsujikawa A, et al., (2012): Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 154: 125-136.